

Invited Lecture

October, 20 (Fri.) 14:30 ~ 15:05 Room 1 (Sonic City Hall 1F LARGE HALL)

Chair Toru Kikuchi (Department of Pediatrics, Saitama Medical University)

The use of technology for achieving Time in Range and Time in Tight range

Tadej Battelino

University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia

KSPE-JSPE Plenary Lecture

October, 20 (Fri.) 15:10 ~ 15:40 Room 1 (Sonic City Hall 1F LARGE HALL)

Chair Noriyuki Namba (Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine)

Molecular and Clinical Characteristics of Monogenic Diabetes in Korean Children

Chong Kun Cheon

Pusan National University School of Medicine, Yangsan, Korea / Pusan National University Children's Hospital, Yangsan, Korea

English Oral Session 1

October 21 (Sat.) 10:45 ~ 11:25 Room 3 (Sonic City Hall 4F INTER NATIONAL CONFERENCE ROOM)

Chairs Asako Tajima (Division of Endocrinology and Metabolism, Saitama Children's Medical Center)
Yukihiro Hasegawa (Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center)

EO1-1 Once-weekly Somapacitan in Japanese Children with GH Deficiency: 2-year Results from REAL4

Yasuko Fujisawa¹, Yasuko Fujisawa¹, Jun Mori², Yasuhisa Ohata³, Yukihito Sato⁴, Sebastian Rohrich⁵, Michael Højby Rasmussen⁶, Rikke Beck Bang⁷, Reiko Horikawa⁸

¹Dept. of Pediatr., Hamamatsu Univ. Sch. of Med.,

²Div. of Pediatr. Endo. and Metabolism, Children's Medical Center, Osaka City General Hosp.,

³Dept. of Pediatr., Osaka Univ. Grad. School of Med.,

⁴Novo Nordisk Pharma Ltd., Tokyo, Japan,

⁵Global Medical Affairs, Rare Endo. Disorders, Novo Nordisk Health Care AG, Zurich, Switzerland,

⁶Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark,

⁷Novo Nordisk A/S, Aalborg, Denmark,

⁸Div. of Endo. and Metabolism, Nat. Center for Child Health and Dev.

EO1-2 Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency

Jun Mori¹, Rasmus Juul Kildemoes², Yassine Kamal Lyauk², Joanne C. Blair³, Bradley S. Miller⁴, Michael Højby Rasmussen², Philippe F. Bäckeljauw⁵

¹Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan,

²Novo Nordisk A/S, Søborg, Denmark,

³Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom,

⁴Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children's Hospital, Minneapolis, Minnesota, USA,

⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

EO1-3 Patient preference questionnaire response after switching to somapacitan after taking daily growth hormone: 2-year results from REAL 4

Jun Mori¹, Joanne C. Blair², Bradley S. Miller³, Michael Hojby Rasmussen⁴, Aristides Maniatis⁵, Volker Böttcher⁶, Ho-Seong Kim⁷, Rikke Beck Bang⁸, Lasse De Fries Jensen³, Michel Polak⁹, Reiko Horikawa¹⁰

¹Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan,

²Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom,

³Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children's Hospital, Minneapolis, Minnesota, USA,

⁴Novo Nordisk A/S, Søborg, Denmark,

⁵Rocky Mountain Pediatric Endocrinology, Centennial, CO, USA,

⁶Division of Pediatric Endocrinology and Metabolism, MVZ Endokrinologikum Frankfurt am Main, Frankfurt, Germany,

⁷Department of Pediatrics, Severance Children's Hospital, Institute of Endocrinology, Yonsei University College of Medicine, Seoul, Republic of Korea,

⁸Novo Nordisk A/S, Aalborg, Denmark,

⁹Service d'Endocrinologie, Gynécologie et Diabétologie Pédiatriques, Hôpital Universitaire Necker Enfants Malades Paris, Assistance Publique-Hôpitaux de Paris, Paris, France,

¹⁰Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan

EO1-4 Effect of Once-Weekly Somatrogen and Once-Daily Somatropin on Body Mass Index and Metabolic Parameters: Post Hoc Analysis of the Pivotal Phase 3 Trial

Mohamad Maghnie¹, Aristides Maniatis², Cheri Deal³, Lawrence Silverman⁴, Monica Nijher⁵, Michael Wajnrajch^{6,7}, Marc Thomas⁵, Jose Cara⁶

¹Clinica Pediatrica, IRCCS Istituto Giannina Gaslini, and DINOGLI, University of Genova,

²Rocky Mountain Pediatric Endocrinology, Centennial, CO, USA,

³Centre de recherche CHU Ste-Justine, Université de Montréal, Montréal, Canada,

⁴Goryeb Children's Hospital, Morristown, NJ, USA,

⁵Pfizer Ltd, Tadworth, UK, ⁶Pfizer Inc, New York, NY, USA,

⁷New York University, Grossman School of Medicine, New York, NY, USA

English Oral Session 2

October 21 (Sat.) 11:25 ~ 11:55 Room 3 (Sonic City Hall 4F INTERNATIONAL CONFERENCE ROOM)

Chairs Kenichi Kashimada (Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU))

Eiichiro Satake (Genetics and Epidemiology, Joslin Diabetes Center)

EO2-1 Persistence to growth hormone treatment and clinical characteristics of paediatric patients with growth hormone deficiency: A retrospective database study

Sumito Dateki¹, Yukihito Sato², Jun Mori³

¹Dept. of Pediat., Nagasaki Univ. Graduate School of Biomedical Sciences, Nagasaki, Japan,

²Novo Nordisk Pharma Ltd., Tokyo, Japan,

³Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan

EO2-2 A case of Graves' disease diagnosed after treatment of idiopathic nephrotic syndrome in childhood

Chisato Narita¹, Naoto Nishizaki², Noriyuki Takubo³, Naoto Shimura¹, Toshiaki Shimizu⁴

¹Dept. of Pediatr. / Tokyo Rinkai Hosp. ,

²Dept. of Pediatr., Juntendo Univ. Sch. of Med. / Urayasu Hosp. ,

³Dept. of Pediatr., Juntendo Univ. Sch. of Med. / Juntendo Hosp.,

⁴Dept. of Pediatr., Juntendo Univ. Grad. Sch. of Med.

EO2-3 Long-term effectiveness and safety of growth hormone therapy in Japanese children with short stature due to Noonan syndrome: real-world data.

Koji Muroya¹, Masanobu Kawai², Hiroyuki Yamagishi³, Takaaki Endo⁴, Alberto Pietropoli⁵,
Reiko Horikawa⁶

¹Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center,

²Department of Gastroenterology, Nutrition and Endocrinology, Research Institute, Osaka Women's and Children's Hospital,

³Division of Pediatric Cardiology, Department of Pediatrics, Keio University School of Medicine,

⁴Novo Nordisk Pharma Ltd., Medical affairs department,

⁵Novo Nordisk Health Care AG,

⁶Division of Endocrinology and Metabolism, National Center for Child Health and Development